ClinicalTrials.gg
Active, not recruitingNCT06660667Updated Jul 16, 2026

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

A Phase 1/2 interventional study of SAR402663 and Diluent in Neovascular Age-related Macular Degeneration, sponsored by Sanofi. Active, not recruiting at 26 sites in 2 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Planned enrollment
214th of 491
66 · median 55
Started
2024
with 23 others
Phase 1/2
61 of 645
7 open now
Primary completion
2027-05
later than 50 of 124 live
Registered
583rd of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 214th largest by planned enrollment of the 491 interventional ones that give a count, is one of 24 that started in 2024, is one of 61 in phase 1/2, reaches primary completion later than 50 of the 124 other live ones, and was the 583rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular age-related macular degeneration.

Participants will be enrolled in one of 2 parts:

  • In Part I (dose escalation), multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants
  • In Part II (dose expansion), participants will be randomized to receive one of two dose levels selected based on data from Part I. Participants, investigators and outcomes assessors will be masked to dose.

After receiving one-time dose of SAR402663, participants will undergo regular assessments over 12 months. Following this, participants will enter an extended follow-up (EFU) phase for the assessment of safety and durability of clinical activity of SAR402663 through Year 5.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 50 and 90 years of age
  • Participants with diagnosis of macular neovascularization secondary to age-related macular degeneration (nAMD)
  • Study eye with best corrected visual acuity (BCVA) ETDRS Snellen equivalent for dose escalation (Part I) between 20/32 and 20/400 and for expansion (Part II) between 20/25 and 20/200
  • Current or previous use of anti-vascular endothelial growth factor (VEGF) treatment in the study eye
  • Demonstrated a response to anti-VEGF treatment

Exclusion criteria

Exclusion Criteria:

  • Any condition in the study eye that may prevent visual acuity improvement or interfere with ocular safety or efficacy assessments
  • History of active ocular infection in the study eye in 6 months prior to screening
  • Active uncontrolled glaucoma in the study eye
  • History of uveitis in either eye
  • Current use of ocular in the study eye
  • Previous gene therapy
  • Any significant poorly controlled illness that would preclude study compliance and follow up

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Part I - SAR402663 open-label (OL)

    Participants will receive a single dose of SAR402663 on Day 1. Multiple dose levels of SAR402663 will be evaluated in successive cohorts of participants.

    Biological: SAR402663 · Drug: Diluent

  • Experimental
    Part II - SAR402663 Dose A

    Participants will receive a single dose of SAR402663 on Day 1.

    Biological: SAR402663 · Drug: Diluent

  • Experimental
    Part II - SAR402663 Dose B

    Participants will receive a single dose of SAR402663 on Day 1.

    Biological: SAR402663 · Drug: Diluent

Interventions

  • BiologicalSAR402663

    Pharmaceutical form:Liquid formulation-Route of administration:Intravitreal injection

  • DrugDiluent

    Pharmaceutical form:Liquid solution-Route of administration:Intravitreal injection

06

What researchers measure

Primary outcomes

  1. Incidence and severity of ocular treatment emergent adverse event (TEAEs)

    Time frame: Day 1 to Week 52

  2. Incidence and severity of ocular treatment emergent serious adverse event (TESAEs)

    Time frame: Day 1 to Week 52

  3. Incidence and severity of non-ocular TEAEs

    Time frame: Day 1 to Week 52

  4. Incidence and severity of non-ocular TESAEs

    Time frame: Day 1 to Week 52

  5. Number of participants with any clinically significant changes in laboratory variables

    Time frame: Day 1 to Week 52

  6. Number of participants with any clinically significant changes in vital signs

    Time frame: Day 1 to Week 52

Secondary outcomes

  1. Percentage of participants not requiring supplemental anti- vascular endothelial growth factor (VEGF) therapy

    Time frame: Day 1 to Week 52 and Week 8 to Week 52

  2. Annualized injection rates of anti-VEGF therapy

    Time frame: Day 1 to Week 52

  3. Change from baseline in BCVA using the ETDRS letter score

    Visual function of the study eye was assessed at a distance of 4 meters using the best corrected visual acuity (BCVA) early treatment diabetic retinopathy study (ETDRS) letter score. BCVA scale range is 0 (worst score) to 100 (best score).

    Time frame: Baseline, Week 52

  4. Percentage of participants not losing more than or equal to 15 ETDRS letters from baseline

    Time frame: Baseline, Week 52

  5. Change from baseline in central subfield thickness (CST), measured by spectral domain optical coherence tomography (SD-OCT)

    Time frame: Baseline, Week 52

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2027, 29 months after the start.

Of 52 phase 1/2 interventional studies under Macular Degeneration, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 28, 2024
StartActual
Nov 21, 2024
Primary completionEst.
May 18, 2027
CompletionEst.
Jun 30, 2031
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06660667
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 28, 2024
Start date
Nov 21, 2024
Primary completion
May 18, 2027 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Jul 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion